A disruptive technology to tackle brain cancer and glioblastoma
News
Clinical Database Lock Completed for the HTX-GBM-01 Trial
Hemerion completed the database lock for its HTX-GBM-01 clinical study on September 28, 2026. This key clinical development milestone formally closes data collection and marks the start of the final… ...
Hemerion is accelerating its international expansion with the granting of new patents in the United States and Japan
In late July 2026, Hemerion was notified of the granting of new patents in two major healthcare markets: the United States and Japan. This international expansion strengthens Hemerion’s intellectual property… ...
Hemerion Research Grant: Two International Awards Presented and a New Edition Announced
To broaden the scope of its research, Hemerion funds initiatives and projects led by scientists or clinical teams capable of offering new perspectives on concrete challenges in the fight against… ...
Stay tuned to our clinical advances













